GNE-3511 is primarily investigated for its potential in cancer therapy, particularly targeting specific pathways involved in tumor growth and survival. It is being studied for its ability to inhibit certain enzymes or proteins that play a critical role in cancer cell proliferation. Researchers are exploring its efficacy in treating various types of cancers, including those resistant to conventional therapies. Additionally, GNE-3511 is being evaluated in preclinical and clinical trials to assess its safety, pharmacokinetics, and optimal dosing regimens. Its application could offer a novel approach to personalized medicine, especially for patients with limited treatment options.